Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Visual benefit versus visual gain: What is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Fungal infection after endothelial keratoplasty: Association with hypothermic corneal storage

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Macular spatial distribution of preserved autofluorescence in patients with choroideremia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Early postnatal hyperglycaemia is a risk factor for treatment-demanding retinopathy of prematurity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Deep anterior lamellar keratoplasty: dissection plane with viscoelastic and air can be different

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low physical activity and higher use of screen devices are associated with myopia at the age of 16-17 years in the CCC2000 Eye Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cohort Profile: The Copenhagen Child Cohort Study (CCC2000)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Retinal arteriolar wall-to-lumen ratios at 16-17 years in the Copenhagen Child Cohort 2000 Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reply: Is automated screening for DR indeed not yet ready as stated by Grauslund et al?

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations

Background: This study aimed to elucidate visual benefits of ranibizumab in patients with neovascular age-related macular degeneration (nAMD) compared with control arms and identify factors affecting response. Methods: This is a post-hoc pooled analysis of two phase III studies, ANCHOR and MARINA, of ranibizumab for the treatment of nAMD. ANCHOR included 83 international sites. MARINA included 96 sites in the USA. Analysis included patients (control, n=323; ranibizumab, n=332) with nAMD and a baseline best-corrected visual acuity (BCVA) of ≥35-<85 letters. Results: Patients receiving ranibizumab achieved an adjusted mean BCVA superiority of 18.9 and 21.2 letters over 12 and 24 months, respectively, compared with control. Ranibizumab treatment, higher baseline BCVA, lower age and smaller lesion size were positively associated with the ability to achieve BCVA >69 letters. Patients with the highest baseline BCVA had lowest BCVA gains. Ranibizumab treatment, lower baseline BCVA, lower age and smaller lesion size were identified as significant predictors of BCVA gain from baseline at month 24 (all p<0.0001). However, the difference in mean BCVA gains at month 24 between treatment and control groups was similar for all baseline BCVA subgroups (≥35-<55 letters, 21.9 letters; ≥55-<70 letters, 25.2 letters; ≥70-<85 letters, 19.3 letters). Conclusions: Higher baseline BCVA is associated with lower BCVA gains but a greater likelihood of achieving good final BCVA >69 letters due to smaller gains needed to achieve response. Visual benefits, including maintenance of visual acuity (VA), final VA achieved and relative gain compared with natural disease progression, should be considered when assessing treatment response in nAMD.

Original languageEnglish
JournalBritish Journal of Ophthalmology
Volume104
Issue number5
Pages (from-to)672-677
Number of pages6
ISSN0007-1161
DOIs
Publication statusPublished - May 2020

Bibliographical note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

    Research areas

  • retina, vision

ID: 59452306